CA Patent

CA1339136C — Amorphous form of aztreonam

Assigned to ER Squibb and Sons LLC · Expires 1997-07-29 · 29y expired

What this patent protects

The non-crystalline, amorphous form of [3S-[3.alpha.(Z),4.beta.]]-3[[2-amino-4-thiazolyl [1-carboxy-1-methylethoxy)imino]acetyl] amino]-4-methyl-2-oxo-1-azetidinesulfonic acid and its pharmaceutically acceptable salts is prepared.

USPTO Abstract

The non-crystalline, amorphous form of [3S-[3.alpha.(Z),4.beta.]]-3[[2-amino-4-thiazolyl [1-carboxy-1-methylethoxy)imino]acetyl] amino]-4-methyl-2-oxo-1-azetidinesulfonic acid and its pharmaceutically acceptable salts is prepared.

Drugs covered by this patent

Patent Metadata

Patent number
CA1339136C
Jurisdiction
CA
Classification
—
Expires
1997-07-29
Drug substance claim
No
Drug product claim
No
Assignee
ER Squibb and Sons LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.